Day: January 23, 2024
MONTREAL, Jan. 23, 2024 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or “the Company”) today provides details on the timeline of events leading up to Glenn Chamandy’s removal as CEO.
For more than a month, Browning West and Glenn Chamandy have claimed that the Board of Directors carried out a flawed CEO succession process. The facts, backed by years of documentation and Mr. Chamandy’s own words, tell a much different story.
In December 2021, the Board and Mr. Chamandy agreed to an orderly three-year succession plan. Had Mr. Chamandy abided by his agreement, rather than attempting to entrench himself as CEO, the recent turmoil at Gildan would have been avoided.
We now know that Mr. Chamandy never intended to abide by the agreed succession plan. He made that clear when he told the Globe and Mail on December...
Celestica Recognized as one of Canada’s Top 100 Employers for Young People for 2024
Written by Customer Service on . Posted in Public Companies.
TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing, hardware platform and supply chain solutions for the world’s most innovative companies, has been named one of Canada’s Top 100 Employers for Young People for 2024 by Mediacorp Canada Inc., organizers of the annual Canada’s Top 100 Employers project.
“We are honoured to be named among Canada’s Top 100 Employers for Young People in 2024,” said Rob Mionis, President and Chief Executive Officer, Celestica. “At Celestica, we recognize that our employees play an important role in our company’s success and we strive to create a collaborative environment that fosters innovation, empowers people and leverages individual expertise.”
Leila Wong, Chief Human Resources Officer, Celestica added, “Our young people play a vital role...
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Written by Customer Service on . Posted in Public Companies.
SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Capital Market.
On January 23, 2023, SAB received notice from Nasdaq that the Company was not in compliance with the Rule, as its common shares failed to meet a closing bid price of $1.00 or more for 30 consecutive business...
Shapeways Announces 100% YOY Growth in its Multi-Million-Dollar Automotive Vertical
Written by Customer Service on . Posted in Public Companies.
Expanded Tier 1 Supplier & OEM Awards Accelerate Growth
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) — Shapeways Holdings, Inc. (NASDAQ: SHPW), a global leader in the large and fast-growing digital manufacturing industry, announced today a landmark 100% year-over-year growth within its multi-million-dollar automotive business. Shapeways Enterprise Manufacturing Solutions continues to secure Tier 1 supplier and OEM direct multi-year production volume, including a recently expanded $1.5M contract with an industry-leading American automotive manufacturer.
Aidan O’Sullivan, General Manager of Enterprise Manufacturing Solutions at Shapeways, noted, “Flexibility and adaptability are key in meeting our customers’ dynamic production demands. Whether it’s rapid, iterative prototyping or market shifts between electric and conventional...
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
Written by Customer Service on . Posted in Public Companies.
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common stock. All of the shares in the proposed offering are to be sold by Sagimet. In addition, Sagimet expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of its Series A common stock in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC,...
Vision Sensing Acquisition Corp. Received Nasdaq Delisting Determination Letter and Intends to Appeal the Determination and Request a Stay Pending the Appeal Hearing
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company” or “VSAC”), a special purpose acquisition company, announced today that it received a staff determination letter (the “Letter”), on January 17, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the determination from the Nasdaq Staff (the “Staff”) to delist the Company’s securities from The Nasdaq Stock Market, because, as of December 26, 2023, the Company had not regained compliance with the requirement set forth Listing Rule 5450(b)(2)(A) that requires the market value of the Company’s listed securities to be $50,000,000 or more.
The Letter also states that since the Company has not yet filed its Form...
Baker Hughes Announces Fourth-Quarter and Full-Year 2023 Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Fourth-quarter highlightsIET orders of $3,030 million, the fifth consecutive quarter above $3 billion.
Net income attributable to the Company of $439 million, up $257 million year-over-year.
GAAP diluted EPS of $0.43 and adjusted diluted EPS* of $0.51.
Adjusted EBITDA* of $1,091 million, above $1 billion for the first time in company history.
Cash flows from operating activities were $932 million and free cash flow* was $633 million.
Shareholder distributions of $521 million, including $320 million of share repurchases.Full-year highlightsIET orders of $14.18 billion, 12% higher than last year’s prior record level.
Net income attributable to the Company of $1,943 million, up $2,544 million year-over-year.
Adjusted EBITDA* of $3.76 billion, increasing 26% year-over-year.
GAAP diluted EPS of $1.91 and adjusted diluted EPS* of...
First Busey Corporation Announces 2023 Fourth Quarter Earnings
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
CHAMPAIGN, Ill., Jan. 23, 2024 (GLOBE NEWSWIRE) — First Busey Corporation (Nasdaq: BUSE)Net Income of $25.7 millionDiluted EPS of $0.46Fourth Quarter 2023 HighlightsAdjusted net income1 at $29.1 million, or $0.52 per diluted common share
Entered into a definitive agreement to acquire Merchants & Manufacturers Bank Corporation (“M&M”), the holding company for Merchants & Manufacturers Bank (“M&M Bank”)
Executed a two-part balance sheet repositioning related to the securities portfolio, expected to be both capital and earnings accretive
Non-performing assets declined 34.4% during the fourth quarter of 2023, to $7.9 million, now representing 0.06% of total assets
Annualized quarterly net charge-off ratio of 0.02% and full year net charge-off ratio of 0.03%
Tangible book value per common share1 of $16.62...
Timbercreek Financial Declares January 2024 Dividend
Written by Customer Service on . Posted in Dividend Reports And Estimates.
TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on February 15, 2024 to holders of Common Shares of record on January 31, 2024.
The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees.
Pursuant to the Plan and at the discretion of Timbercreek Capital Inc., the Manager, Common Shares will be acquired in the open market at prevailing prices or issued from treasury at 98 percent of the average market price...
Stallion Uranium Announces Listed Issuer Financing Exemption (LIFE) Non-Brokered Private Placement of Units
Written by Customer Service on . Posted in Public Companies.
Not for distribution to United States Newswire Services or for dissemination in the United States
VANCOUVER, British Columbia, Jan. 23, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: HM40) is pleased to announce that it is undertaking a non-brokered private placement (the “Offering“) for aggregate gross proceeds of up to C$4,000,000, with an over-allotment option to raise up to an additional C$1,000,000 of Units (as defined below), from the sale of the following:up to 4,687,500 Federal flow-through units of the Company (each, an “FFT Unit”) at a price of C$0.32 per FFT Unit;
up to 4,166,667 Saskatchewan flow-through units of the Company (each, a “SFT Unit”) at the price of C$0.36 per SFT Unit; and
up to 4,545,454 units of the Company...